Eli Lilly 'Deserves' Stock Upside: Analyst
Bullish strength: 78/100
- Q3 revenue and EPS both significantly exceeded expectations
- Strong revenue growth from weight-loss drugs Mounjaro and Zepbound
Bearish strength: 22/100
- Adjusted EPS guidance slightly lowered
This is automated NewsSignals analysis of third-party reporting, not independent original reporting or investment advice. AI scores are not price predictions.